Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 9Nivolumab 4Fluorouracil 4Mohs Surgery 3talimogene laherparepvec 2atezolizumab 2Therapeutics 2Photochemotherapy 2Petrolatum 2Paclitaxel 2Niacinamide 2Aminolevulinic Acid 2tozuleristide 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1selinexor 1regorafenib 1peginterferon alfa-2b 1peginterferon alfa-2a 1osimertinib 1nanocis 1methyl 5-aminolevulinate 1fludarabine 1daromun 1cobimetinib 1cemiplimab 1avelumab 1aldesleukin 1aflibercept 1afamelanotide 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Excipients × Dermatologic × Clear all
NCT02844777 2023-01-12

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Vidac Pharma

Phase 2 Completed
93 enrolled 13 charts
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡